ERBB2 and breast cancer: Indeed, although the availability of a plethora of promising anti-HER2 compounds has improved the prognosis of the HER2+ BC subtype, tumor recurrence due to de novo or acquired refractoriness of tumor cells to current treatments remains a major concern.